Baseline and longitudinal changes of benign prostate specific antigen and [-2]proprostate specific antigen in community dwelling black and white men
Citation & Export
Hide
Simple citation
Rhodes, Thomas.
Baseline and longitudinal changes of benign prostate specific antigen and [-2]proprostate specific antigen in community dwelling black and white men. Retrieved from
https://doi.org/doi:10.7282/T37P8XPBExport
Description
TitleBaseline and longitudinal changes of benign prostate specific antigen and [-2]proprostate specific antigen in community dwelling black and white men
Date Created2011
Other Date2011-05 (degree)
Extentxii, 116 p. : ill.
DescriptionProstate specific antigen (PSA) is used extensively in the detection of prostate cancer (CaP) but it is not specific to malignant tissue. Subforms of PSA have been identified which are more specific to benign and malignant tissue. Benign prostate specific antigen (BPSA) is associated with pathologic benign prostatic hyperplasia (BPH), while [-2]proPSA is associated with CaP. Little is known about these biomarkers in community-based men. The objectives were to: (1) describe the distribution of BPSA and [-2]proPSA in a community-based sample of men and examine their association with baseline urologic measures and outcomes, (2) describe the distribution of longitudinal changes in BPSA and [-2]proPSA and how these changes vary by urologic conditions. Data from two cohorts established to characterize the natural history of prostate disease in white and black men of Olmsted County, MN (OC) and Genesee County, MI, respectively. The distribution of BPSA levels was similar in blacks (median (25th, 75th percentiles) =32.9 (17.3, 68.0) pg/mL) and whites (median=32.2 (16.6, 68.9) pg/mL). For OC men in the upper quartile of BPSA, there was a 15-fold increased risk of CaP (hazard ratio (HR): 14.6, 95% confidence interval (CI): 3.1, 68.6) and a 2-fold higher age-adjusted risk of treatment for BPH (HR: 2.2, 95% CI: 1.2, 4.2). Baseline [-2]proPSA level was slightly higher among blacks (median (25th, 75th percentiles; Q1 Q3) =6.3 (4.1, 8.9) pg/mL) than among whites (median=5.6 (3.9, 7.7) pg/mL). Relative to men in the lower quartile of [-2]proPSA, men in the upper quartile had an 8-fold increase in the age- and PSA-adjusted risk of CaP (hazard ratio (HR): 7.8, 95% confidence interval (CI): 2.2, 27.8). Median (Q1,Q3) annual percent change for [-2]proPSA and BPSA were 3.7% (2.5%, 5.2%) and 7.3%(6.8%, 7.7%), respectively. Annual percent change in [-2]proPSA increased with age. The median (Q1, Q3) rate of increase in [-2]proPSA was greater for men who developed enlarged prostates (3.5% (2.6%, 4.4%)) or CaP (8.1% (6.6%, 9.8%)) compared to those who did not develop enlarged prostates (1.9% (0.9%, 3.0%)) or CaP (3.5% (2.3%, 4.8%)). These data provide useful reference ranges for future studies of these biomarkers. Further study is needed.
NotePh.D.
NoteIncludes bibliographical references
NoteIncludes vita
Noteby Thomas Rhodes
Genretheses, ETD doctoral
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Statistical Profile